LUNG CANCER IN PATIENTS WITH PULMONARY FIBROSIS: CHARACTERISTICS FEATURES AND PROGNOSIS

Basit Öğe Kaydı
dc.contributor.authorKara, Sibel
dc.contributor.authorMo, Nesrin
dc.contributor.authorKirkil, Gamze
dc.contributor.authorCetinkaya, Erdogan
dc.contributor.authorOzbudak, Omer
dc.contributor.authorKilic, Talat
dc.contributor.authorUcsular, Fatma Demirci
dc.date.accessioned2026-04-04T13:30:54Z
dc.date.available2026-04-04T13:30:54Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground and aim: Lung cancer is one of the significant comorbidities seen in patients with Idiopathic Pulmonary Fibrosis (IPF). However, there is limited data on non-IPF Pulmonary Fibrosis (PF) patients with lung cancer (LC). The present study aims to compare the characteristics and survival outcomes of patients diagnosed with LC in IPF and non-IPF PF. Methods: The multicenter data records of IPF and non-IPF PF patients diagnosed with lung cancer between 2010-2022 were analyzed in this descriptive, cross-sectional, and retrospective study. Results: Of the 251 patients involved in this study [164 IPF-LC, 87 non-IPF PF-LC], 89.6% were male, the mean age was 69 +/- 7.9 years and the smoking rate was 85.7%. Honeycomb pattern was more frequently observed in IPF-LC patients [62.8%,37.9%p<0.001], whereas ground-glass opacity [33.5%,59.8%p<0.001] and emphysema [37.8%,59.8%p<0.001] were more frequently seen in non-IPF PF-LC patients. The most commonly seen histological type was squamous cell carcinoma [42.7%,33.9%], followed by adenocarcinoma [28.2%; 32.2%]. [46.4%;47.2%] and their 5-year mortality rates were high [64.6%, 63.2%]. The median survival for both groups was 2 +/- 0.22 years [median 95% CI (1.55-2.44)]. The shortest survival time was observed in non-IPF PF-LC subIPF and non-IPF PF LC patients were male, elderly, and had a high smoking rate. Squamous cell carcinoma was the most frequently seen histological type and they had short survival periods and high mortality rates. The survival period of unclassified non-IPF PF-LC patients was found to be the shortest.
dc.identifier.doi10.36141/svdld.v41i4.15675
dc.identifier.issn1124-0490
dc.identifier.issue4
dc.identifier.orcid0000-0003-1870-5669
dc.identifier.orcid0009-0003-2682-6070
dc.identifier.orcid0000-0002-0507-0767
dc.identifier.pmid39655590
dc.identifier.urihttps://doi.org/10.36141/svdld.v41i4.15675
dc.identifier.urihttps://hdl.handle.net/11616/108463
dc.identifier.volume41
dc.identifier.wosWOS:001376867800018
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMattioli 1885
dc.relation.ispartofSarcoidosis Vasculitis and Diffuse Lung Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectpulmonary fibrosis
dc.subjectidiopathic pulmonary fibrosis
dc.subjectlung cancer
dc.subjectradiology
dc.subjecthistology
dc.subjectmortality
dc.titleLUNG CANCER IN PATIENTS WITH PULMONARY FIBROSIS: CHARACTERISTICS FEATURES AND PROGNOSIS
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu